Mar. 25 at 8:29 PM
$NKTX Nkarta reports Q4 EPS (37c), consensus (29c)
Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of
$295.1M as of December 31, 2025. "2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible steward of investor capital, and continued to advance our CAR-NK cell therapy platform through dose escalation in the clinic," said Paul Hastings, CEO of Nkarta. "Thoughtfully leveraging our safety data, we are now dosing patients at 4 billion cells in a three-dose cycle for a total of 12 billion cells as we look to maximize the depth and durability of B-cell depletion and clinical response, positioning us to unlock the full potential of NKX019 for people living with autoimmune disease."
